Rapport Therapeutics to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Rapport Therapeutics (Nasdaq: RAPP) announced management will participate in two upcoming investor conferences in November 2025: a fireside chat at the Stifel 2025 Healthcare Conference in New York on Nov 13, 2025, 1:20–1:50pm ET, and a fireside chat at the Jefferies Global Healthcare Conference in London on Nov 17, 2025, 1:00–1:25pm GMT (8:00–8:25am ET).
Interested parties can access live and archived webcasts via the company’s Investors website at https://investors.rapportrx.com.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, RAPP declined 3.10%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
BOSTON and SAN DIEGO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that management plans to participate in the following upcoming investor events:
Stifel 2025 Healthcare Conference (New York City, NY) – fireside chat on Thursday, November 13, 2025, at 1:20-1:50pm ET.
Jefferies Global Healthcare Conference (London, UK) – fireside chat on Monday, November 17, 2025, at 1:00-1:25pm GMT/8:00-8:25am ET.
Interested parties may access the live and archived webcasts of the fireside chats under the “Investors” section of the company’s website at: https://investors.rapportrx.com.
About Rapport Therapeutics
Rapport Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing small molecule precision medicines for patients with neurological or psychiatric disorders. The Company’s founders have made pioneering discoveries related to the function of receptor associated proteins (RAPs) in the brain. Their findings form the basis of Rapport’s RAP technology platform, which enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Rapport’s precision neuroscience pipeline includes the Company’s lead investigational drug, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. The Company is currently pursuing RAP-219 as a potential treatment for drug-resistant focal onset seizures, bipolar mania and diabetic peripheral neuropathic pain. Additional preclinical and late-stage discovery stage programs are also underway, including targeting chronic pain and hearing disorders.
Contact
Julie DiCarlo
Head of Communications & IR
Rapport Therapeutics
jdicarlo@rapportrx.com
FAQ
When is Rapport Therapeutics (RAPP) presenting at the Stifel 2025 Healthcare Conference?
What time is the Rapport Therapeutics (RAPP) fireside chat at Jefferies Global Healthcare Conference in London?
How can investors watch Rapport Therapeutics (RAPP) conference webcasts?
Will Rapport Therapeutics (RAPP) provide a replay of the conference presentations?
What topics will Rapport Therapeutics (RAPP) likely cover at the November 2025 investor conferences?
Are the Rapport Therapeutics (RAPP) conference events open to the public or limited to investors?
